** Shares of vaccine maker Moderna MRNA.O fall 1.4% to $27.60 premarket
** Co says it is voluntarily withdrawing its marketing application for its COVID-flu combination vaccine for adults aged 50 years and older
** Co plans to resubmit its application later this year, after late-stage efficacy data of its experimental seasonal influenza vaccine, mRNA-1010, is available
** The company's decision comes a day after the U.S. Food and Drug Administration said it would require new clinical trials for approval of annual COVID-19 boosters for healthy people under 65 years
** "Moderna continues to expect interim data from the mRNA-1010 trial to be available this summer", co says
** Up to last close, stock down 32.7% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.